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Abstract
Background: Resistance to thyroid hormones is a very rare condition, which is often misdiagnosed and mistreated.
The cases where there is a concomitant autoimmune thyroid disorder are ultra-rare and particularly challenging to
treat. Diagnostic and research-based genomic testing can sometimes identify pathogenic variants unrelated to the
primary reason for testing (incidental findings).
Case presentation: We present a patient with thyroid resistance associated with hypothyroid Hashimoto thyroiditis.
The long diagnostic odyssey spanning over 20-years included repeated misdiagnoses and mistreatments and was
concluded by a research-based genomic testing, identifying a “de novo” THRB pathogenic variant. The varying
sensitivity of various tissues to thyroid hormones accompanied by hypothyroid Hashimoto thyroiditis continues to
pose a significant treatment challenge.
Conclusions: Thyroid hormone resistance continues to be an un(der)- and misdiagnosed thyroid condition whose
management is particularly challenging when associated with autoimmune thyroid disease. Whole exome sequencing
has the potential to identify THRB pathogenic variants as incidental findings. Reporting such secondary findings from
genomic testing may be particularly important in the context of the rarity of the condition and the potential clinical
consequences of misdiagnosis and mistreatment.
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Introduction
Resistance to thyroid hormones – RTH (OMIM 190160,
188570, 145650) is a rare condition characterised by
increased levels of thyroid hormones (particularly free
fractions, fT4, fT3) and inappropriately unsuppressed
levels of TSH, often in the normal or even increased range
[1–3]. Although the true prevalence of this condition is
not known, it is considered to be a very rare condition af-
fecting about 1 in 40000 people, with about 3000 patients
described worldwide so far [1–3].
The classical RTH is an autosomal dominant condition
due to either germline inherited or ‘de novo’ dominant
negative pathogenic variants in the THRB gene (coding
for the beta subunit of the thyroid hormone receptor,
THRβ), rendering the thyroid receptor less responsive to
the thyroid hormones [1–3]. Mosaic forms of RTH due to
pathogenic variants in THRβ have also been described [4].
The variable expression of THRβ in various tissues result-
ing in varying degrees of relative thyroid deficit and the
increased T4/T3 signalling through the unaffected THRα
make it difficult to understand the genotype - phenotype
relationship and to make sense of the laboratory results and
interpret them in the context of the clinical features in
RTH [5, 6]. The clinical features in RTH are highly variable,
even within the same family harbouring the same THRβ
pathogenic variant [5]. Most patients with RTH present
with goitre and/or tachycardia, hyperactive behaviour, and
about half of the patients have neurocognitive symptoms
including emotional disturbances, anxiety, learning diffi-
culty, developmental delay and intellectual disability. Most
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patients reach normal stature, but children can have lower
body weight and height [1, 3, 7].
The syndrome of RTH, like other rare conditions, poses
complex diagnostic and treatment challenges and can lead
to long and expensive diagnostic odysseys and suboptimal
patient care [8–10]. The diagnostic power of genomic test-
ing based on next generation sequencing, has revolutio-
nised the field of rare diseases [11, 12]. Notwithstanding
its diagnostic utility, genomic testing also introduced some
challenges, such as reporting of incidental (and/or second-
ary) findings, particularly in the context of genomic testing
of children [13, 14]. Despite the ability of genomics to
provide diagnosis in 20–60% cases, access to genetic
services remains a major challenge in the developing
low- and middle-income countries due to lack of gen-
etic resources, infrastructure and expertise [15, 16].
We present a complex case of resistance to thyroid hor-
mones and Hashimoto thyroiditis (HT) with a long diag-
nostic odyssey ended by genomic testing in a research
setting and discuss the challenges of diagnosis and clinical
management of this patient with RTH-related unusual thy-
roid hormones homeostasis combined with a HT-related
hypothyroid state.
Case report
The patient is the elder of two sisters in the family, born
prematurely at 7-month gestation to non-
consanguineous parents and had normal development.
She presented for medical attention at age 19 with
Jackson-type seizures and was referred for her first thy-
roid evaluation (6/91, Table 1) due to a history of ner-
vousness, heat intolerance, mild sleep disturbance and
Table 1 Patient’s diagnostic and management odyssey
Date Symptoms T4
fT4
T3
fT3
TSH TAB Size Treatment
6/91 nervous, palpitation, sweating > 200
n/a
4.2
n/a
1.4 aMS+ N start tiamazol
9/91 feeling better < 47
n/a
n/a n/a n/a 2.5 N reduced tiamazol
3/92 no symptoms > 320
n/a
4.0
n/a
1.9 n/a 2.5 N 2months no treatm ?
high ThyH carriers
4/93 tremor, tachycardia, weight loss > 340
n/a
n/a 2.1 n/a n/a start tiamazol
6/93 no change 279
n/a
n/a n/a n/a n/a discontinued ? high
ThyH carriers
1/94 nervous tachycardia 257
38
n/a 1.4 n/a n/a start tiamazol
5/94 asymptomatic 173
n/a
n/a n/a n/a n/a discontinued
9/94 asymptomatic 228
46
2.2
n/a
1.2 n/a n/a metimazol
11/94 asymptomatic 206
28
2.2
n/a
1.4 n/a n/a discontinued ?
ThyH resistance
9/96 asymptomatic 250
93
2.1
14
1.9 n/a n/a no treatment
TRH test following 7 days T3 overload – normal TSH response (basal TSH 0.23, 30′ 2.1, 60′ 1.2, 90′ 0.89)
DNA sent to overseas lab for genetic testing, returned no result.
until 8/2007 to 184
to 79
to 3.2
to 9.5
to 2.7 aHTG 37.5
aTPO 1642
N firm no treatment ? HT
until 12/2015 lost to follow up
RA on MTX, bioTx
sought international thyroid expertise, diagnosed and treated for
thyrotoxicosis due to elevated fT4, fT3 and despite unsuppressed TSH
12/15 tired, slow
weight gain
n/a
31.4
n/a
14.3
5.6 n/a firm hyperECH ThyH replacement
Hypothyroid HT
2018 Patient recruited in an international study of genetics of autoimmunity and underwent whole exome
sequencing providing genetic confirmation of the RTH (pathogenic variant in THB, p.Arg338Trp).
2019
Abbreviations and normal laboratory values: TRH – thyrotropin releasing hormone, RA – rheumatoid arthritis, MTH – methotrexate, T4 – total T4 (units μg/ml,
normal 5–14.1), fT4 – free T4 (units pmol/L, normal 11–21), T3 – total T3 (units ng/ml, normal 0.8–2.1), fT3 – free T3 (units pmol/L, normal 3.1–6.0), TSH (units mU/
ml, normal 0.4–4.3), ThyH – thyroid hormone(s), aMS – antimicrtosomal antibodies, aHTG – antihuman thyroglobulin antibodies, aTPO – antitissue peroxidase
antibodies, hyperECH – hyperechogenic, HT – Hashimoto thyroiditis, RTH – resistance to thyroid hormones, THB – thyroid hormone receptor, beta subunit, n/a –
not assessed
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heart palpitations. Clinically, she was tachycardic (96
bpm), with sweaty hands, slightly palpable thyroid gland,
with no tremor and normal blood pressure. A diagnosis
of hyperthyroidism was made based on elevated thyroid
hormone levels, and positive antimicrosomal antibodies,
despite the unsuppressed TSH levels and the patient was
started on antithyroid treatment (6/91, Table 1). In the
course of the following 3 years the patient was on and
off antithyroid treatment due to exaggerated response to
tiamazol (9/91, Table 1) with varying clinical symptoms
consistent with hyperthyroid state (4/93). There was a
suspicion of high levels of thyroid hormone carriers,
which was ruled out by high fT4 levels (1/94, Table 1).
The first clinical suspicion of RTH was documented in
11/94 and corroborated by the high levels of total and free
thyroid hormones and unsuppressed TSH, and a result
from TRH test under suppression with high dose T3 con-
sistent with RTH. The patient remained without treatment
for the following 10-years, and was lost to follow up during
the subsequent 8 years. During this period, the patient
sought international thyroid expertise, and was diagnosed
and treated for thyrotoxicosis based on high total and free
thyroid hormone levels and some symptoms consistent
with a hyperthyroid state, despite unsuppressed TSH levels.
Of note, during this period she was diagnosed with a mod-
erate to severe rheumatoid arthritis (RA) and treated with
methotrexate and subsequently with biologic therapy.
In 12/15 (Table 1) the patient presented to our depart-
ment complaining of feeling tired, slow and intolerant to
cold, with levels of thyroid hormones lower and TSH level
higher than her usual, elevated levels of cholesterol and
weight gain of 17 kg over the preceding 8-year period.
Those findings together with positive antithyroid anti-
bodies, palpatory firm gland with non-homogenous hyper-
echogenic ultrasound appearance lead to the diagnosis of
hypothyroid Hashimoto thyroiditis and she was initiated
on thyroid replacement treatment.
In 2018 our patient was recruited in an international re-
search study approved by the Human Genetic Committees
of the Australian National University and The Canberra
Hospital and underwent whole exome sequencing. The
details of the used genomic and bioinformatic method-
ology is described elsewhere [17]. This testing identified a
“de novo” pathogenic variant (with confirmed paternity
and maternity, data not shown) in the beta subunit of the
thyroid hormone receptor, THRB p.Arg228Trp) leading to
RTH (Fig. 1). This variant has been described in more
than 30 families/cases with RTH so far [18], and has not
been described in the databases of human variation
(dbSNP, 1000 genomes). The variant affects an evolution-
ary highly conserved amino acid, is predicted to be dam-
aging/deleterious by in silico prediction tools (PolyPhen,
SIFT), and in vitro studies have shown that this variant af-
fects T3 binding to the thyroid hormone receptor [19].
The patient continues to be treated with low doses
thyroid replacement therapy, mostly based on clinical
features, taking into consideration her personal usual
levels of thyroid hormones and TSH. The ongoing
Fig. 1 Patient’s pedigree and results from genetic testing. Whole exome sequencing identified a heterozygous “de novo” pathogenic variant
NM_001252634.1(THRB):c.1012C > T changing evolutionary conserved amino acid Arg338 to Trp (p.Arg338Trp). The variant was not found in the
healthy parents (I:1, I:2) and sister (II:1), both maternity and paternity was confirmed with microsatellite testing (data not shown)
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challenge is judging her thyroid state clinically given the
variable distribution of alpha and beta thyroid hormone
receptors leading to discrepant symptoms of hyperthy-
roidism (tachycardia, sweating) and hypothyroidism
(hypercholesterolemia, weight gain, cold intolerance).
Discussion
We present an unusual and rare case of rare RTH and
hypothyroid HT. As other in other cases, the RTH in our
case was initially misdiagnosed and mistreated as auto-
immune thyrotoxicosis aiming to reduce thyroid hormone
levels, which should be avoided particularly in pregnant
patients [3, 20–23]. We would argue that the same holds
true in (young) children with RTH, where antithyroid
treatment could be dangerous and potentially detrimental
to the intellectual development. Unfortunately, given no
prior clinical experience with this very rare condition and
lack of access to genetic testing services and clinical genet-
ics support, the diagnosis of RTH in this patient was not
confirmed until 24 years later. This long diagnostic odys-
sey contributed to patient’s mistrust and frequent change
of thyroid specialists, which at some stage lead to the cor-
rect clinical diagnosis of thyroid hormone resistance, but
also prompted the patient to seek second opinions from
thyroid physicians, including international experts, which
ultimately lead to repeated misdiagnosis and mistreatment
with antithyroid medications.
Our case was made more challenging by the co-
existence of HT, formally diagnosed later in the course
of the disease. For a while, the thyroid autoimmune
process in our patient was detectable only on level of
positive thyroid autoantibodies and later it manifested
with increasing level of thyroid autoantibodies, ultra-
sonographic changes consistent with inflammation and
overt clinical hypothyroidism with increased levels of
TSH (compared to the usual in this patient) - established
the diagnosis of HT and prompted treatment with thy-
roid hormone replacement which is ongoing at this
point in time [24]. The association between autoimmun-
ity and RTH and the possible underlying mechanisms
remain anecdotal [25] and there are isolated reports of
both RTH associated with Graves disease [26–30] and
Hashimoto thyroiditis [31–36] – all emphasising the
diagnostic and management challenges posed by these
associations, cautioning about the possibility of errone-
ous diagnosis and treatment.
Our case is unusual in that the genetic diagnosis was
established by genomic testing, using whole exome se-
quencing. While the genetic test did not find a causative
variant for the immune-mediated conditions in the patient
(RA and HT), it detected a pathogenic THRB variant caus-
ing RTH. This finding could be considered an “incidental”
finding in the context of the primary autoimmunity focus
of our research project, and pose the dilemma of reporting
an incidental finding for a condition (RTH) which affects
the same organ (thyroid axis) as the primary condition
(HT) [13]. This consideration prompted us to ask the
question whether the THRB gene should be nominated
for the list of reportable “actionable” incidental findings
[13, 37]. In the context of increased use of genomic testing
in children (including young children and even newborn
babies), it is plausible that there may be instances where
children with RTH and pathogenic THRB variants are se-
quenced for unrelated reasons, but would benefit greatly
from having the information about having RTH, which
could prevent misdiagnosis and potentially harmful conse-
quences of iatrogenic hypothyroidism induced by treat-
ment with antithyroid medications. We also wonder about
the full applicability of the protocol used to assess the
“clinical actionability” associated with genomic variation
[37] in the context of such a rare disease as RTH, for
which it may be a while before we have clinical practice
guidelines, or high-level evidence from systemic reviews
and/or meta-analyses.
Conclusion
In conclusion, RTH is a very rare and often misdiagnosed
and mistreated condition, often creating a long diagnostic
odyssey due to lack of access to genetic services. When
recognised RTH poses a significant treatment challenge,
particularly when combined with a more common auto-
immune thyroid disease. Elevated levels of thyroid hor-
mones, particularly fT4 and fT3, with unsuppressed TSH
levels should raise suspicion of RTH and prompt referral
to a tertiary thyroid centre with capacity to differentiate
and established this rare diagnosis.
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